Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02242630 · ClinicalTrials.gov registry record · NA
Relationship to Dose of Triamcinolone Acetonide and Methylyprednisolone to Improvement in Subacromial Bursitis
A NA study, sponsored by Keesler Air Force Base Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 61
- Enrollment target
NCT02242630 is a NA study that has completed, run by Keesler Air Force Base Medical Center. The registered enrollment target is 61 participants.
The verdict
NCT02242630, a NA study, has completed, sponsored by Keesler Air Force Base Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 61 participants
- Enrollment target
Study Summary
It is currently unknown whether or not the improvement in pain and function related to a "steroid shot" for shoulder pain due to subacromial bursitis is important. This study seeks to determine whether 20 mg or 40 mg of either triamcinolone or methylprednisolone significantly affect improvement in shoulder pain 6 weeks after injection.
Interventions
- DRUG Methylprednisolone, 20 mg
- DRUG Methylprednisolone, 40 mg
- DRUG Triamcinolone, 20 mg
- DRUG Triamcinolone, 40 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02242630
The ClinicalTrials.gov registry entry for NCT02242630 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Keesler Air Force Base Medical Center, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Methylprednisolone, 20 mg is the first listed.
NCT02242630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02242630 about?
NCT02242630 is a clinical study titled "Relationship to Dose of Triamcinolone Acetonide and Methylyprednisolone to Improvement in Subacromial Bursitis". It is currently unknown whether or not the improvement in pain and function related to a "steroid shot" for shoulder pain due to subacromial bursitis is important. This study seeks to determine whether 20 mg or 40 mg of either triamcinolone or methylprednisolone significantly affect improvement in s...
What is the current status of trial NCT02242630?
This trial is currently completed. It is a NA study. The enrollment target is 61 participants. The study started on 2014-09. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02242630?
The interventions under investigation include: Methylprednisolone, 20 mg (DRUG), Methylprednisolone, 40 mg (DRUG), Triamcinolone, 20 mg (DRUG), Triamcinolone, 40 mg (DRUG).
Who is sponsoring clinical trial NCT02242630?
This trial is sponsored by Keesler Air Force Base Medical Center, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.